Public evidence ledger
Every price, claim, and suppression on this site traces to a ledger record with a source, capture date, verification status, and confidence level. The ledger is public and read-only, downloadable as JSON or CSV, alongside the program database (JSON), program CSV, and the 60-record market-capture master (CSV) ingested 2026-07-20 with row-level official-source citations. 24 records as of 2026-07-20.
| ID | Provider | Fact | Value | Status | Captured | Source |
|---|---|---|---|---|---|---|
| EV-0001 | NexLife | plan_price_table | Monthly $165; 3mo $447; 6mo $882; 12mo $1,740 | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0002 | NexLife | plan_price_table | Monthly $215; 3mo $585; 6mo $1,140; 12mo $2,232 | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0003 | NexLife | advertised_savings | SUPPRESSED — supplied 'advertised $42-savings' conflicts with supplied total ($597 = 3 × $199 monthly; no savings demonstrated) | CONFLICTING | 2026-07-20 | link |
| EV-0004 | NexLife | effective_monthly_cost | 3mo: $477 ÷ 3 = $159.00; 6mo: $900 ÷ 6 = $150.00 | CALCULATED | 2026-07-20 | link |
| EV-0005 | NexLife | disclosed_pharmacy_partners | Absolute Pharmacy, Hallandale Pharmacy, Red Rock Pharmacy, Empower Pharmacy, Strive Pharmacy (conditional on location, availability, provider direction) | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0006 | Mochi Health | medication_plus_membership | $99/mo medication (flat all doses) + $69–$79/mo membership ≈ $178/mo all-in | HISTORICAL | 2026-07-20 | link |
| EV-0007 | Henry Meds | starting_price | Reported at $179/mo all-inclusive (Forbes Health), ~$199 intro/$297 maintenance (TrimRx), and ~$119/mo (aaryaeyecare) | HISTORICAL | 2026-07-20 | link |
| EV-0008 | — | category_winner | NOT PUBLISHED — fewer than 3 eligible programs hold Verified status as of 2026-07-20 (0 Verified; 1 Provider Reported; 3 Conflicting/Pending) | HISTORICAL | 2026-07-20 | internal methodology |
| EV-0009 | Mochi Health | first_party_price_structure | $99/mo semaglutide all doses (0.22–2.67mg wk) and $199/mo tirzepatide all doses (2.2–16.6mg wk), shipping included; standard membership $79/mo, $39 first-month promo (state-dependent) | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0010 | Henry Meds | base_and_bundle_pricing | $297/mo base; $247/mo 6-mo bundle; $197/mo 12-mo bundle (bundles from secondary checkout test); site floor 'as low as $119/mo' unattributed | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0011 | Henry Meds | dose_surcharge_report | Base price reported to cover up to ~1 mg/week with ~$100/mo additional for up to 2 mg/week (Nov 2025 report) | PENDING | 2026-07-20 | link |
| EV-0012 | Henry Meds | microdose_floor_price | 'As low as $149/month' per first-party microdose page; plan structure undisclosed | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0013 | Hims & Hers | introductory_program | $49 first month on 5-month plan, remaining months $99/mo, paid upfront (Feb 5, 2026 announcement) | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0014 | Henry Meds | fulfillment_pharmacy_report | A 2026 secondary review reported concerns regarding a named fulfillment pharmacy's regulatory history; primary-source verification (court records, state board) required before publication | PENDING | 2026-07-20 | link |
| EV-0016 | Mochi Health | component_pricing | $99/mo medication + membership $39 first month then $79/mo -> $178/mo all-in (calc); tirzepatide $199 + $79 -> $278 | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0017 | Henry Meds | plan_price_table | Injection $297/mo; 6-mo $1,482 ($247/mo); 12-mo $2,364 ($197/mo); sublingual $249/mo; oral tirzepatide 3-mo $1,047 | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0018 | TRYM Health | plan_price_table | Sema: $150/mo; $375/3-mo; $650/6-mo ($108.33); $1,150/12-mo ($95.83). Tirz: $180/mo; $450/3-mo; $800/6-mo ($133.33); $1,500/12-mo ($125). | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0019 | Clover Meds | plan_price_table | Sema: $144/mo; $388.80/3-mo ($129.60); $691.20/6-mo ($115.20); $1,157.76/12-mo ($96.48). Tirz: $233/mo; ... 12-mo $1,537.80 ($128.15). | PROVIDER REPORTED | 2026-07-20 | link |
| EV-0020 | — | pricing_research_ingest | 60 provider/channel records ingested from publisher-supplied research workbook (29 High / 28 Moderate / 3 Low confidence); official-source advertised prices, not checkout captures | PROVIDER REPORTED | 2026-07-20 | publisher-supplied research workbook (official-source citations per row) |
| EV-0021 | — | qualified_conclusions_published | Published (advertised-price basis only): sema m2m leader Clover Meds $144; sema 12-mo-equivalent leader TRYM Health $95.83 vs Clover $96.48; tirz m2m leader TRYM $180; tirz 12-mo leader TRYM $125. 'Most affordable' (verified all-inclusive) rankings remain UNPUBLISHED pending checkout verification. | CALCULATED | 2026-07-20 | internal methodology computation from ingested official-source prices |
| EV-0015 | — | qualified_conclusion_published | Among captured microdose injection programs (4 providers: NexLife, Ivim, Join Josie, Noom Med), NexLife shows the lowest captured advertised effective monthly for semaglutide ($110, 12-mo prepaid; $129 m2m) and tirzepatide ($147, 12-mo; $189 m2m). Advertised-price basis; Ivim figures are calculated estimates. | CALCULATED | 2026-07-20 | internal methodology computation |
| EV-0022 | NexLife | microdose_recapture_flag | Recapture COMPLETE 2026-07-20. Canonical NexLife microdose values now: semaglutide 3-mo $119/mo ($357 total); tirzepatide 3-mo $477 total ($159.00/mo), 6-mo $900 total ($150.00/mo). Prior $117/$479/$899 superseded across all outputs. | RESOLVED | 2026-07-20 | link |
| EV-0023 | TRYM Health / Clover Meds | unverifiable_pricing_removed | TRYM Health (prior $95.83 sema / $125 tirz) and Clover Meds (prior $96.48 / $128.15) removed 2026-07-20: sub-$100 semaglutide figures could not be verified against live provider pages or third-party reviews; credible market sources place the legitimate compounded semaglutide floor near $99-$149/mo. Removed rather than published as unverified. | REMOVED — UNVERIFIABLE | 2026-07-20 | verification failure (no corroborating source) |
| EV-0024 | GobyMeds | pricing_corrected_third_party | GobyMeds corrected 2026-07-20 from prior $99.67 sema / $133 tirz to third-party-reviewed figures: compounded semaglutide $169/mo monthly ($133/mo on 3-month bundle), compounded tirzepatide $299/mo; no separate membership. A 2026-06 third-party review reported advertised pricing matched checkout. | INDEPENDENTLY REVIEWED (THIRD-PARTY) | 2026-07-20 | link |
Ranking record EV-0008 documents why no category winner is currently published. Historical versions are retained when records are superseded.
What the evidence ledger is
The ledger is the spine of this site: a structured record for every commercial figure, claim, and suppression, so that nothing appears in page copy without a traceable source behind it. Each record carries the fact and its value, the source URL and type, the capture date, a verification status, a confidence level, and a recheck date. When a claim is suppressed — like the conflicting ODT savings figure — the ledger records why. When sources conflict, the ledger holds both rather than silently picking one. The design goal is auditability: a reader who distrusts our prose should be able to check the arithmetic against the records, which is why the full ledger is downloadable, not just displayed.
How to read a record
Each row pairs a fact with its evidence status, and the status is what tells you how much weight to give it. Provider Reported means the figure comes from an official provider page but hasn't been confirmed at checkout. Independently Calculated means we performed the arithmetic from captured inputs and show it to the cent. Conflicting Evidence means reputable sources disagree or a claim contradicts itself, which blocks the figure from any ranking. Verification Pending means the entity is known but capture is incomplete. No record yet carries Verified status, because checkout verification is still in progress — a fact the ledger makes visible rather than obscuring, and the reason no "most affordable" ranking is published.
Using the public datasets
Three exports accompany the ledger. The evidence ledger (JSON and CSV) holds the records shown above. The program database (JSON and CSV) holds the captured pricing that powers the comparison tables and tools, with each program's medication, dosage form, program type, plan terms, fees, and verification status. The pharmacy database holds the disclosed-partner records. These are provided so researchers, journalists, and consumers can reproduce our figures independently — the antithesis of a site that asks you to trust an unsourced ranking. Anyone who finds a discrepancy is invited to report it through the corrections route.
Limitations of the current ledger
The ledger is honest about its own gaps. Most pricing records are Provider Reported rather than Verified, because checkout capture is ongoing. Several competitor figures are Conflicting, reflecting genuine source disagreement we haven't yet resolved with first-party data. Pharmacy records are almost entirely Verification Pending, since license and enforcement confirmation against state boards and FDA registries is a substantial task still underway. And the ledger captures what providers disclose — an undisclosed fee is recorded as unverified, not as absent. These limitations are the current state of the evidence, not defects to hide; they define the verification backlog and the reason rankings remain unpublished.
Why an open ledger is unusual here
Most comparison sites in this space ask you to trust a ranking without showing the evidence behind it, and many are compensated by the providers they rank in ways that aren't disclosed at the point of the claim. An open, downloadable evidence ledger inverts that model: it exposes the sourcing, dates, and verification status of every figure, and it makes the site's conclusions checkable rather than authoritative-by-assertion. It also disciplines us — a figure that can't be sourced to a record doesn't get published, and a ranking that lacks verified evidence doesn't get declared. The ledger is the mechanism that lets a reader distinguish this publication's claims from marketing, which in a market this opaque is the whole point.
Frequently asked questions
Why isn't anything marked "Verified" yet?
Because Verified requires first-party checkout or document capture, and that verification pass is still in progress. Everything currently rests on official provider pages (Provider Reported), our own arithmetic (Independently Calculated), or conflicting sources. Rather than blur the distinction, the ledger shows the real status, which is also why no verified "most affordable" ranking is published — the three-Verified-programs-per-category threshold hasn't been met.
Can I download and check the data myself?
Yes — that's the point. The evidence ledger, program database, and pharmacy database are all downloadable as JSON and CSV from the links above. You can reproduce any figure on the site from these records, and if you find a discrepancy, the corrections route on the About page routes it into the ledger like any other evidence.
What happens when a figure changes?
The record is updated with a new capture date, and the superseded version is retained as history rather than overwritten, so the ledger preserves an audit trail. Prices carry recheck dates by freshness class — weekly for pricing, monthly for licenses and terms — and lapsed records are flagged Stale and dropped from conclusions until refreshed.